Treating depression in acute stage: biochemical and clinical aspects

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depression treatment has evolved over 50 years, guided by amine theories and leading to selective serotonin reuptake inhibitors (SSRIs).
• Previous cerebrospinal fluid (CSF) research focused on amine metabolites, limiting understanding of neurotransmitter dynamics in depression.

Purpose of the Study:

• To revise amine theories of depression by measuring parent neurotransmitters in CSF.
• To investigate the impact of antidepressant treatments on CSF neurotransmitter levels in animal models.

Main Methods:

• International cooperation enabled direct measurement of parent neurotransmitters in human CSF.
• Analysis of CSF neurotransmitter levels in untreated depressed patients.
• Animal studies examining CSF adrenaline and noradrenaline changes following monoamine oxidase inhibitor (MAOI) and citalopram administration.

Main Results:

• Untreated depression showed low CSF adrenaline, normal noradrenaline, and increased serotonin and dopamine.
• MAOIs increased CSF adrenaline in animal models.
• Long-term citalopram treatment affected CSF noradrenaline levels in animal models.

Conclusions:

• Findings necessitate a major revision of current amine theories of depression.
• The biology of depression likely involves a wider range of neurotransmitters than previously considered.
• Interactive counterregulations may diminish the initial selectivity of antidepressant drugs.